quilizumab   Click here for help

GtoPdb Ligand ID: 8998

Synonyms: 47H4 v5 hulgG1 [4] | MEMP1972A | RG-7449
Immunopharmacology Ligand
Compound class: Antibody
Comment: Quilizumab is a humanized IgG1κ investigational monoclonal antibody designed to bind the M1' segment of membrane-bound immunoglobulin E (mIgE), which is part of the B-cell receptor (BCR) on B cells [1].
Peptide sequences and 3D structural information for this antibody are available from its IMGT/mAb-DB record.
BLAST peptide analysis reveals 100% matches with sequences claimed in patent US8071097 B2 [4].
Click here for help
No information available.
Summary of Clinical Use Click here for help
A Phase 2 clinical trial evaluating quilizumab as a treatment for refractory chronic spontaneous urticaria (NCT01987947) has been completed. The quilizumab development programme was terminated. Alternative anti-IgE agents are still in development, including United BioPharma's UB-221 (humanized anti-IgE mAb; Phase 1 chronic urticaria) [2] and DARPin-based IgE inhibitors [3].
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT01987947 A Study of Quilizumab Versus Placebo in Patients With Refractory Chronic Spontaneous Urticaria Phase 2 Interventional Genentech, Inc.